||EPS - Basic
||Market Cap (m)
Smiths Group Share Discussion Threads
Showing 976 to 994 of 1000 messages
|Goldman raises tp from 1800p to 1850p ... Buy|
|Smiths Group announces completion of acquisition of Morpho Detection
|6th april HSBC buy tp 1900p up from 1700p|
|xd tomorrow morning for the 13.55p dividend|
|Smiths Group: Market Is Undervaluing Improvements Even At 52-Week Highs
|30th march RBC outperform tp 1750p up from 1700p|
|28th march Goldmans buy tp 1800p up from 1740p|
|27th march JP Morgan overweight tp 1730p up from 1612p|
|'Sprawling Smiths Group looks to divest as it refocuses'
|As Smiths Group updates the market Graham Spooner, our investment research analyst, explains what it could mean for investors:
Smiths Group reported increase in profits and revenues and stuck to its full-year outlook boosted by growth in its detection unit
The group’s new strategy announced last September is being implemented and aims to increase competitiveness and outperformance in its markets.
We recommend Smiths Group as a ‘buy’ for medium risk investors seeking a balanced return
|Telegraph market report:
.....Elsewhere, forecast-beating half-year results lifted engineering firm Smiths to the top of the leaderboard, up 45p to £16.01. Operating profit rose 27pc to £277m boosted by cost cuts and growth in its detection unit. The group also maintained its full-year outlook. Following the upbeat results, Credit Suisse increased its price target from £16 to £17.40, adding its investment case “remains attractive”.
|Stifel analysts described the results as “very strong” and better than expected.
“Smiths says that the outlook for the year is unchanged, but we think that this is conservative,” they wrote in a note to clients. “There is clear evidence of both operational and strategic progress here.”
|Impressive numbers :-)|
|In at the start.
Smiths Group has boosted its first-half pretax profit and revenue by double-digit percentages, as well as lifting its dividend, accompanied wiht an unchanged outlook for full-year 2017.
"In the past six months we have made good progress to focus our portfolio and run our businesses better," said chief executive Andy Smith.
He said strong cash conversion and improved margins across the group provided it with additional resources to invest for the future.
"By laying the foundations for organic growth through targeted investments and by taking a disciplined approach to acquisitions and disposals, we are building a bigger, better and more focused Smiths," he added.
Pretax profit was £248m, up 31% from £189m, with revenue coming in at £1.6bn, up 18% from £1.4bn. Interim dividend was 13.55p a share, up from 13.25p.
"Overall, the outlook for 2017 is unchanged," said the CEO, Smith.
"Group performance is expected to be slightly weighted towards the second half, albeit with a more balanced split between the first and second half than we saw last year."
Smith expected some improvement in Smiths Medical's revenue performance in the second half.
John Crane's first-fit end markets were expected to remain tough, somewhat counterbalanced by continued resilience in aftermarket.
"We anticipate sales growth at Smiths Detection in the second half, albeit at lower levels than we saw in the first half, and margins will moderate given contract mix and investment in new products," he said.
Smiths Interconnect and Flex-Tek were expected to continue to perform in line with the first half.
"We expect cash conversion to continue to be strong as the rate of progress on inventory management improves. The depreciation of sterling is expected to provide a tailwind to reported revenue and operating profit, should current rates prevail."|
|20th march Numis buy tp 1810p
|Nice breakout today .|
|13th march JP Morgan overweight tp 1612p
|Smith Interconnect unifies its brands
|Hopefully 1500p holds. Not too many buyers about.|